Abstract

Several laboratories have reported the reprogramming of mouse and human fibroblasts into pluripotent cells, using retroviruses carrying the Oct4, Sox2, Klf4, and c-Myc transcription factor genes. In these experiments the frequency of reprogramming was lower than 0.1% of the infected cells, raising the possibility that additional events are required to induce reprogramming, such as activation of genes triggered by retroviral insertions. We have therefore determined by ligation-mediated polymerase chain reaction (LM-PCR) the retroviral insertion sites in six induced pluripotent stem (iPS) cell clones derived from mouse fibroblasts. Seventy-nine insertion sites were assigned to a single mouse genome location. Thirty-five of these mapped to gene transcription units, whereas 29 insertions landed within 10 kilobases of transcription start sites. No common insertion site was detected among the iPS clones studied. Moreover, bioinformatics analyses revealed no enrichment of a specific gene function, network, or pathway among genes targeted by retroviral insertions. We conclude that Oct4, Sox2, Klf4, and c-Myc are sufficient to promote fibroblast-to-iPS cell reprogramming and propose that the observed low reprogramming frequencies may have alternative explanations.

Highlights

  • A major goal of current stem cell research is the use of specialized cells obtained from patient-derived embryonic stem (ES) for therapeutic purposes

  • We have determined by ligation-mediated polymerase chain reaction (LM-PCR) the retroviral insertion sites in six induced pluripotent stem cell clones derived from mouse fibroblasts

  • To test whether there are recurrent integration sites in individually derived induced pluripotent stem (iPS) clones generated with retroviral vectors that might point to as yet unknown collaborating reprogramming factors, we determined the integration sites of six different iPS clones derived from murine fibroblasts

Read more

Summary

Introduction

A major goal of current stem cell research is the use of specialized cells obtained from patient-derived embryonic stem (ES) for therapeutic purposes. Similar results were reported from other laboratories [2, 3] and for human cells [4] Common to these studies is the low frequency of cell reprogramming, estimated to be approximately 0.1% or less in all cases. On the basis of repeated detections of specific genes targeted by integration in independently derived tumors from retrovirus infected mice, viral insertion strategies have been used to identify proto-oncogenes [9]. More recently this strategy was successful in identifying genes that help to expand the hematopoietic stem cell pool [10, 11]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call